HMN 2025: How Urine-based tumor DNA check might assist personalize bladder cancer remedy

In a multi-institutional study published within the European Urology journal, researchers revealed that testing urine-based tumor DNA (utDNA) may also help predict which bladder cancer sufferers are at larger threat for recurrence after remedy.

This study analyzed utDNA from sufferers within the SWOG S1605 trial, who have been handled with atezolizumab, an immunotherapy drug. Researchers used the UroAmp check to look at urine samples from 89 sufferers in the beginning of remedy and from 77 sufferers three months later. The aim was to see if utDNA might assist establish which bladder cancer sufferers are most certainly to answer immunotherapy.

“This strategy might assist enhance affected person care by guiding more practical remedies and supporting extra customized plans,” mentioned Robert Svatek, MD, MSCI, professor and chair of urology on the Joe R. and Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). “It means we might be able to tailor remedy sooner, scale back pointless delays and assist sufferers keep away from main surgical procedure with out compromising the standard of their care.”

The SWOG S1605 study was a part 2 scientific trial testing atezolizumab in sufferers with high-risk bladder cancer that did not reply to BCG (Bacillus Calmette-Guérin) remedy, the principle immunotherapy to deal with early-stage bladder cancer.

Samples have been collected from contributors earlier than remedy and once more three months later. Researchers used the UroAmp assay, a noninvasive urine check that detects bladder cancer–associated mutations, to investigate utDNA and generate a genomic profile for every affected person.

They discovered that utDNA ranges have been linked to how properly sufferers responded after six months and the way lengthy they stayed cancer-free over 18 months. Patients with constructive utDNA outcomes have been much less prone to reply and extra prone to have their cancer return.

According to the American Cancer Society, bladder cancer is the sixth most typical cancer within the United States, with greater than 83,000 new instances identified yearly. Of these instances, roughly 75% are non–muscle invasive, that means the cancer has not but invaded the bladder muscle.

Patients who do not reply to immunotherapy might face the tough resolution of both persevering with therapies that spare the bladder however carry excessive dangers of recurrence or endure main surgical procedure that removes the bladder and profoundly impacts one’s high quality of life.

This study presents new hope for sufferers with high-risk bladder cancer by displaying {that a} urine-based DNA check may also help predict who’s extra prone to profit from immunotherapy. By figuring out remedy response early, this strategy might information extra customized, bladder-preserving care and scale back the necessity for main surgical procedure.